40
Participants
Start Date
July 7, 2025
Primary Completion Date
September 30, 2026
Study Completion Date
December 31, 2026
Tirzepatide
Tirzepatide will be initiated at a dose of 2.5 mg weekly and increased as tolerated to 5 mg weekly at four weeks for the remainder of the 9-month intervention period. Participants who are unable to tolerate the 5 mg dose will be decreased to the 2.5 mg dose.
RECRUITING
Wake Forest University Health Sciences, Winston-Salem
Wake Forest University Health Sciences
OTHER